Cubist and Durata Heat Up Antibiotic Market

Whether Cubist Pharmaceuticals or Durata Therapeutics wins remains to be seen, but both might be able to beat Pfizer's older drug.

Jun 23, 2014 at 5:30PM

Antibiotics are on a comeback. And Cubist Pharmaceuticals (NASDAQ:CBST) is in the middle of it.

Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second antibiotic in as many months: Durata Therapeutics' (NASDAQ:DRTX) Dalvance last month and Cubist's Sivextro last week.

And last week the agency also gave another of Cubist's antibiotics, ceftolozane/tazobactam, a priority review, which shaves four months off the review of the drug for complicated urinary tract infections and complicated intra-abdominal infections. With a decision expected on or before December 21, Cubist could have two approvals in one year.

Both Durata's Dalvance and Cubist's Sivextro are approved for treating acute bacterial skin and skin structure infections, or ABSSSI, including the nasty methicillin-resistant Staphylococcus aureus, or MRSA, variety that can't be treated with older antibiotics.

Sivextro is available in both intravenous and oral formulations, so patients can transition to the daily oral formulation when they're discharged from the hospital. Dalvance only has to be administered twice, but both doses, administered a week apart, are given intravenously.

It would seem Cubist has the advantage on dosing with the oral formulation, but given the life-threatening nature of MRSA, doctors are more likely to pick a treatment based on efficacy than convenience.

Unfortunately, that's easier said than done at this point. The drugs haven't been compared head to head, and in the clinical trials used to support their approvals, Durata compared Dalvance to Shire's Vancomycin but Cubist compared Sivextro to Pfizer's (NYSE:PFE) Zyvox. Complicating things more, patients in the control group for the Dalvance trials were allowed, but not required, to transition from Shire's Vancomycin to Pfizer's Zyvox after three days.

Both drugs were approved based on clinical trials that showed the drugs are noninferior to their comparators, which is the standard way for an antibiotic to get approved but doesn't tell you much about how good they really are. For Shire the competition isn't a big deal since Vancomycin is already available as a generic, but Pfizer would certainly like to keep the market share Zyvox has. While the efficacy between Sivextro and Zyvox looks similar, Cubist might have Pfizer beat on side effects and certainly has it beat on the convenience front since Sivextro is taken once daily for six days versus twice daily for 10 days for Zyvox.

The fact that we're even talking about competition is a good sign for investors and patients because it means the FDA has woken up and become open to approving new antibiotics. You could argue that the companies have figured out what the FDA wants, and to some degree that's true too, but there's no doubt the Generating Antibiotic Incentives Now part of the Food and Drug Administration Safety and Innovation Act signed into law a few years ago has changed the dynamics of antibiotic drug development.

We're seeing the fruition now. With a pipeline of five drugs including expanded indications for currently approved drugs, Cubist is a company investors should be watching.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Cubist Pharmaceuticals. The Motley Fool owns shares of Cubist Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers